{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T18:52:24Z","timestamp":1766775144569,"version":"3.48.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alpha-2 adrenergic receptor agonists are established therapeutic medications that are used for conditions such as hypertension, pain disorders, muscle relaxation, spasticity, opioid withdrawal, insomnia, and sedation. While forensic toxicologists may be familiar with more common alpha receptor agonists, tizanidine is a less frequently identified compound, with limited published data available regarding antemortem and postmortem concentrations. Tizanidine therapeutic concentrations found in plasma are reported in the range of 0.0025\u20130.025\u2009mg\/L, although CYP1A2 inhibitors can significantly raise tizanidine levels in the body, thereby increasing the risk of dose-related toxicity. Additionally, imidazoline receptor activity is an underappreciated contributor to the mechanism of action and potential for adverse effects of this drug. Due to its high potency, tizanidine may be missed by forensic laboratories that are not targeting this drug or carefully inspecting untargeted data for its presence. In this study, 18 postmortem cases involving tizanidine are reviewed to improve the understanding of its forensic toxicological profile. These cases have been divided into categories as ruled by the certifying pathologist of \u201cSuicide\u201d involving tizanidine (N\u2009=\u20098, mean 6.2\u2009mg\/L and median 0.77\u2009mg\/L) and \u201cAccident\u201d involving tizanidine (N\u2009=\u20094, mean 0.86\u2009mg\/L and median 0.89\u2009mg\/L), and additionally a category of \u201cIncidental\u201d (N\u2009=\u20096, mean 0.35\u2009mg\/L and median 0.035\u2009mg\/L). Comparison of tizanidine concentrations to those in example cases such as this dataset can assist postmortem forensic toxicologists and pathologists in distinguishing therapeutic postmortem concentrations from toxic\/lethal concentrations. However, consideration of scene details and totality of case investigation is essential when determining cause and manner of death.<\/jats:p>","DOI":"10.1093\/jat\/bkaf056","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:47:32Z","timestamp":1749800852000},"page":"594-602","source":"Crossref","is-referenced-by-count":0,"title":["Tizanidine in postmortem forensic cases"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2536-1535","authenticated-orcid":false,"given":"Laura W","family":"Friederich","sequence":"first","affiliation":[{"name":"Department of Health and Human Services, Division of Public Health, North Carolina Office of Chief Medical Examiner , Raleigh, NC 27607,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani C","family":"Mata","sequence":"additional","affiliation":[{"name":"ToxiDani LLC , Garden Grove, CA 92840,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-457X","authenticated-orcid":false,"given":"Sandra C","family":"Bishop-Freeman","sequence":"additional","affiliation":[{"name":"Department of Health and Human Services, Division of Public Health, North Carolina Office of Chief Medical Examiner , Raleigh, NC 27607,","place":["United States"]},{"name":"Department of Pathology and Laboratory Medicine, University of North Carolina , Chapel Hill , NC 27599,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2025122613495443700_bkaf056-B1","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt","year":"2020","edition":"12th edn."},{"key":"2025122613495443700_bkaf056-B2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","article-title":"Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders","volume":"53","author":"Wagstaff","year":"1997","journal-title":"Drugs"},{"key":"2025122613495443700_bkaf056-B3","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2147\/JPR.S461032","article-title":"Tizanidine: advances in pharmacology & therapeutics and drug formulations","volume":"17","author":"Zhu","year":"2024","journal-title":"J Pain Res"},{"key":"2025122613495443700_bkaf056-B4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","article-title":"A review of spasticity treatments: pharmacological and interventional approaches","volume":"25","author":"Chang","year":"2013","journal-title":"Crit Rev Phys Rehabil Med"},{"key":"2025122613495443700_bkaf056-B5","first-page":"427","article-title":"Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain","volume":"39","author":"Witenko","year":"2014","journal-title":"P T"},{"volume-title":"StatPearls","year":"2023","author":"Ghanavatian","key":"2025122613495443700_bkaf056-B6"},{"key":"2025122613495443700_bkaf056-B7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1517\/14656566.9.12.2209","article-title":"Update on tizanidine for muscle spasticity and emerging indications","volume":"9","author":"Malanga","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"2025122613495443700_bkaf056-B8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.clinthera.2007.04.012","article-title":"Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects","volume":"29","author":"Henney","year":"2007","journal-title":"Clin Ther"},{"key":"2025122613495443700_bkaf056-B9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1074248410395020","article-title":"Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking I Kr","volume":"17","author":"Kaddar","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025122613495443700_bkaf056-B10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","article-title":"Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction","volume":"75","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"2025122613495443700_bkaf056-B11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1472-8206.1987.tb00581.x","article-title":"Pharmacokinetics of orally administered tizanidine in healthy volunteers","volume":"1","author":"Tse","year":"1987","journal-title":"Fundam Clin Pharmacol"},{"key":"2025122613495443700_bkaf056-B12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/B978-1-4160-4836-7.00064-X","volume-title":"Current Therapy in Pain","author":"McCleane","year":"2009"},{"key":"2025122613495443700_bkaf056-B13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0168-8278(96)80252-2","article-title":"A case of tizanidine-\u00adinduced hepatic injury","volume":"25","author":"De Graaf","year":"1996","journal-title":"J Hepatol"},{"key":"2025122613495443700_bkaf056-B14","doi-asserted-by":"crossref","first-page":"e623","DOI":"10.1097\/MJT.0000000000000497","article-title":"Importance of medication reconciliation: tizanidine-induced hepatitis","volume":"24","author":"Gill","year":"2017","journal-title":"Am J Ther"},{"key":"2025122613495443700_bkaf056-B15","doi-asserted-by":"crossref","first-page":"1179547618758022","DOI":"10.1177\/1179547618758022","article-title":"Management of tizanidine withdrawal syndrome: a case report","volume":"11","author":"Su\u00e1rez-Lled\u00f3","year":"2018","journal-title":"Clin Med Insights Case Rep"},{"key":"2025122613495443700_bkaf056-B16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1081\/CLT-200026978","article-title":"Retrospective review of tizanidine (Zanaflex\u00ae) overdose","volume":"42","author":"Spiller","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"2025122613495443700_bkaf056-B17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","article-title":"Alpha-2 adrenergic receptor agonists: a review of current clinical applications","volume":"62","author":"Giovannitti","year":"2015","journal-title":"Anesth Prog"},{"key":"2025122613495443700_bkaf056-B18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1254\/jjp.59.457","article-title":"Tizanidine may discriminate between imidazoline-receptors and alpha 2-adrenoceptors","volume":"59","author":"Muramatsu","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"2025122613495443700_bkaf056-B19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3109\/15563650.2014.898770","article-title":"Significance of the imidazoline receptors in toxicology","volume":"52","author":"Lowry","year":"2014","journal-title":"Clin Toxicol (Phila)"},{"key":"2025122613495443700_bkaf056-B20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0014-2999(02)01664-3","article-title":"Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine","volume":"445","author":"Honda","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"2025122613495443700_bkaf056-B21","doi-asserted-by":"crossref","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Dependence"},{"key":"2025122613495443700_bkaf056-B22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.15585\/mmwr.mm7330a3","article-title":"Notes from the field: detection of medetomidine among patients evaluated in emergency departments for suspected opioid overdoses\u2013Missouri, Colorado, and Pennsylvania, September 2020\u2013December 2023","volume":"73","author":"Schwarz","year":"2024","journal-title":"MMWR. Morbidity Mortal Wkly Report"},{"key":"2025122613495443700_bkaf056-B23","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(20)30852-7","article-title":"New directions in the treatment of opioid withdrawal","volume":"395","author":"Srivastava","year":"2020","journal-title":"Lancet"},{"key":"2025122613495443700_bkaf056-B24","first-page":"e36864","article-title":"Xylazine in the opioid epidemic: a systematic review of case reports and clinical implications","volume":"15","author":"Ayub","year":"2023","journal-title":"Cureus"},{"key":"2025122613495443700_bkaf056-B25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/15563650.2020.1863977","article-title":"High dose naloxone for acute tizanidine overdose in the emergency department: a case report","volume":"59","author":"Adams","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"2025122613495443700_bkaf056-B26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12245-021-00397-y","article-title":"Pediatric tizanidine toxicity reversed with naloxone: a case report","volume":"14","author":"Bader","year":"2021","journal-title":"Int J Emerg Med"},{"key":"2025122613495443700_bkaf056-B27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1476-5381.1979.tb08661.x","article-title":"Naloxone reverses the antihypertensive effect of clonidine","volume":"67","author":"Farsang","year":"1979","journal-title":"Br J Pharmacol"},{"key":"2025122613495443700_bkaf056-B28","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/01.CIR.66.6.1268","article-title":"Possible involvement of an endogenous opioid in the antihypertensive effect of clonidine in patients with essential hypertension","volume":"66","author":"Farsang","year":"1982","journal-title":"Circulation"},{"key":"2025122613495443700_bkaf056-B29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/15563650.2018.1450986","article-title":"Naloxone reversal of clonidine toxicity: dose, dose, dose","volume":"56","author":"Seger","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"2025122613495443700_bkaf056-B30","doi-asserted-by":"crossref","first-page":"100155","DOI":"10.1016\/j.addicn.2024.100155","article-title":"Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to opioid antagonism","volume":"11","author":"Bedard","year":"2024","journal-title":"Addiction Neuroscience"},{"key":"2025122613495443700_bkaf056-B31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jat\/30.5.331","article-title":"Tizanidine distribution in a postmortem case","volume":"30","author":"Sklerov","year":"2006","journal-title":"J Anal Toxicol"},{"key":"2025122613495443700_bkaf056-B32","first-page":"9","article-title":"Tizanidine intoxication in a postmortem case","volume":"39","author":"Miller","year":"2015","journal-title":"ToxTalk"},{"year":"2019","author":"Standard 03, Standard Practices for Method Validation in Forensic Toxicology: NSI\/ASB Standard 03","key":"2025122613495443700_bkaf056-B33"},{"key":"2025122613495443700_bkaf056-B34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/dta.1507","article-title":"Drug concentrations in post-mortem femoral blood compared with therapeutic concentrations in plasma","volume":"6","author":"Launiainen","year":"2014","journal-title":"Drug Test Anal"},{"key":"2025122613495443700_bkaf056-B35","first-page":"643","article-title":"Liver, renal, and cardiovascular failure after unintentional overdose of tizanidine in a 2-year-old child","volume":"26","author":"Vila","year":"2021","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaf056\/63508139\/bkaf056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/49\/8\/594\/63508139\/bkaf056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/49\/8\/594\/63508139\/bkaf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T18:50:09Z","timestamp":1766775009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/49\/8\/594\/8165439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,17]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaf056","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"type":"print","value":"0146-4760"},{"type":"electronic","value":"1945-2403"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,17]]}}}